GCP
IMDX

GSA Capital Partners’s Insight Molecular Diagnostics IMDX Stock Holding History

GSA Capital Partners’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,012
Closed -$144K – 1775
2022
Q2 		$144K Buy
8,012
+112
+1% +$2.55K 0.02% 1158
2022
Q1 		$235K Sell
7,900
-4,715
-37% -$151K 0.03% 1069
2021
Q4 		$547K Buy
+12,615
New +$726K 0.07% 534
2021
Q3 		– Sell
-1,882
Closed -$216K – 1679
2021
Q2 		$216K Sell
1,882
-349
-16% -$34.1K 0.02% 1146
2021
Q1 		$232K Sell
2,231
-6,276
-74% -$596K 0.04% 809
2020
Q4 		$407K Sell
8,507
-1,545
-15% -$56.7K 0.07% 555
2020
Q3 		$279K Buy
+10,052
New +$288K 0.05% 792

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

GSA Capital Partners's IMDX Position: Q3 2022 in Review

GSA Capital Partners sold out of Insight Molecular Diagnostics (IMDX) in Q3 2022, closing a stake of 8,012 shares — an estimated $144K sold.

GSA Capital Partners first reported a position in IMDX in Q3 2020 and held it in 7 quarters. The position peaked at $547K in Q4 2021. 65 funds tracked by Wall St. Rank hold IMDX as of Q3 2022.

  • GSA Capital Partners reported no remaining Insight Molecular Diagnostics position as of Q3 2022 after selling out during the quarter.
  • GSA Capital Partners sold 8,012 Insight Molecular Diagnostics shares in Q3 2022, an estimated $144K.
  • GSA Capital Partners first reported a position in Insight Molecular Diagnostics in Q3 2020 and held it in 7 quarters.
  • GSA Capital Partners's Insight Molecular Diagnostics position peaked at $547K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2022.

Based on GSA Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.